Luminex has since fixed the problem with a software update but a similar issue with non-specific amplification has also affected two targets on BioFire's GI panel.
In the quarter the firm acquired food and beverage testing firm Invisible Sentinel and partnered with Baxter International to develop acute kidney injury biomarkers.
The firm also reported full-year 2018 sales of €2.42 billion, a year-over-year increase of 6 percent on a reported basis, or 10 percent organically.
The BioFire FilmArray Pneumonia panel will be used to optimize clinical trial enrollment for an antibiotic to treat combat carbapenem-resistant A. baumannii infections.
Despite a recent positive economic modeling study, the debate over appropriate use of the ME panel seems likely to continue until more outcomes studies are conducted.
The research highlighted particular challenges for gram-negative organisms among a population of higher-risk patients.
The test is the second of three panels intended to detect pathogens that cause the bloodstream infections that can lead to sepsis.
The CDC is leading the way to discover what causes the polio-like syndrome, as hospital labs also continue testing patient samples.
The BioFire FilmArray Pneumonia Panel was cleared by the FDA while the BioFire FilmArray Pneumonia Panel Plus was CE marked.
Clinicians identifying and treating S. aureus bloodstream infections reduced the median length of stay by 5.6 days and hospital cost by $13,341 per patient after using Luminex's assay.